Cargando…

Frontiers in the Standardization of the Plant Platform for High Scale Production of Vaccines

The recent COVID-19 pandemic has highlighted the value of technologies that allow a fast setup and production of biopharmaceuticals in emergency situations. The plant factory system can provide a fast response to epidemics/pandemics. Thanks to their scalability and genome plasticity, plants represen...

Descripción completa

Detalles Bibliográficos
Autores principales: Citiulo, Francesco, Crosatti, Cristina, Cattivelli, Luigi, Biselli, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467261/
https://www.ncbi.nlm.nih.gov/pubmed/34579360
http://dx.doi.org/10.3390/plants10091828
_version_ 1784573352134836224
author Citiulo, Francesco
Crosatti, Cristina
Cattivelli, Luigi
Biselli, Chiara
author_facet Citiulo, Francesco
Crosatti, Cristina
Cattivelli, Luigi
Biselli, Chiara
author_sort Citiulo, Francesco
collection PubMed
description The recent COVID-19 pandemic has highlighted the value of technologies that allow a fast setup and production of biopharmaceuticals in emergency situations. The plant factory system can provide a fast response to epidemics/pandemics. Thanks to their scalability and genome plasticity, plants represent advantageous platforms to produce vaccines. Plant systems imply less complicated production processes and quality controls with respect to mammalian and bacterial cells. The expression of vaccines in plants is based on transient or stable transformation systems and the recent progresses in genome editing techniques, based on the CRISPR/Cas method, allow the manipulation of DNA in an efficient, fast, and easy way by introducing specific modifications in specific sites of a genome. Nonetheless, CRISPR/Cas is far away from being fully exploited for vaccine expression in plants. In this review, an overview of the potential conjugation of the renewed vaccine technologies (i.e., virus-like particles—VLPs, and industrialization of the production process) with genome editing to produce vaccines in plants is reported, illustrating the potential advantages in the standardization of the plant platforms, with the overtaking of constancy of large-scale production challenges, facilitating regulatory requirements and expediting the release and commercialization of the vaccine products of genome edited plants.
format Online
Article
Text
id pubmed-8467261
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-84672612021-09-27 Frontiers in the Standardization of the Plant Platform for High Scale Production of Vaccines Citiulo, Francesco Crosatti, Cristina Cattivelli, Luigi Biselli, Chiara Plants (Basel) Review The recent COVID-19 pandemic has highlighted the value of technologies that allow a fast setup and production of biopharmaceuticals in emergency situations. The plant factory system can provide a fast response to epidemics/pandemics. Thanks to their scalability and genome plasticity, plants represent advantageous platforms to produce vaccines. Plant systems imply less complicated production processes and quality controls with respect to mammalian and bacterial cells. The expression of vaccines in plants is based on transient or stable transformation systems and the recent progresses in genome editing techniques, based on the CRISPR/Cas method, allow the manipulation of DNA in an efficient, fast, and easy way by introducing specific modifications in specific sites of a genome. Nonetheless, CRISPR/Cas is far away from being fully exploited for vaccine expression in plants. In this review, an overview of the potential conjugation of the renewed vaccine technologies (i.e., virus-like particles—VLPs, and industrialization of the production process) with genome editing to produce vaccines in plants is reported, illustrating the potential advantages in the standardization of the plant platforms, with the overtaking of constancy of large-scale production challenges, facilitating regulatory requirements and expediting the release and commercialization of the vaccine products of genome edited plants. MDPI 2021-09-02 /pmc/articles/PMC8467261/ /pubmed/34579360 http://dx.doi.org/10.3390/plants10091828 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Citiulo, Francesco
Crosatti, Cristina
Cattivelli, Luigi
Biselli, Chiara
Frontiers in the Standardization of the Plant Platform for High Scale Production of Vaccines
title Frontiers in the Standardization of the Plant Platform for High Scale Production of Vaccines
title_full Frontiers in the Standardization of the Plant Platform for High Scale Production of Vaccines
title_fullStr Frontiers in the Standardization of the Plant Platform for High Scale Production of Vaccines
title_full_unstemmed Frontiers in the Standardization of the Plant Platform for High Scale Production of Vaccines
title_short Frontiers in the Standardization of the Plant Platform for High Scale Production of Vaccines
title_sort frontiers in the standardization of the plant platform for high scale production of vaccines
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8467261/
https://www.ncbi.nlm.nih.gov/pubmed/34579360
http://dx.doi.org/10.3390/plants10091828
work_keys_str_mv AT citiulofrancesco frontiersinthestandardizationoftheplantplatformforhighscaleproductionofvaccines
AT crosatticristina frontiersinthestandardizationoftheplantplatformforhighscaleproductionofvaccines
AT cattivelliluigi frontiersinthestandardizationoftheplantplatformforhighscaleproductionofvaccines
AT bisellichiara frontiersinthestandardizationoftheplantplatformforhighscaleproductionofvaccines